Luke Nathaniel Walker
Known title: DirectorCIK: 0001701440
Luke Nathaniel Walker's purchase track record
Luke Nathaniel Walker has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/31/2025 | ZNTL | $25K | -16.7% | -23.0% | +3.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZNTL | ▲ Buy | Grant | 57,100 | $0 | 6/16/2026 | View on chart |
| ZNTL | ▲ Buy | Grant | 57,603 | $0 | 6/17/2025 | View on chart |
| ZNTL | ▲ Buy | Open Market | 14,200 | $25K | 1/31/2025 | View on chart |
| ZNTL | ▲ Buy | Grant | 72,481 | $0 | 5/24/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.